Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...
Meet the European companies that raised €100M and more in Q1 2025; 14 of them are currently hiring
According to Dealroom, in Q1 2025, European startups have secured $15.8B through nearly 1,600 funding rounds. From AI and fintech to clean energy and biotech, startups have attracted large amounts of ...
Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...
Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate ... AlphaFold’s success would pave the way for Isomorphic Labs, ...
Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug ...
Isomorphic Labs was founded to apply artificial intelligence to drug discovery. The company is led by AI researcher Sir Demis Hassabis.
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...
The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback